ID   TCC-SUPrGEMCI20
AC   CVCL_RR25
DR   cancercelllines; CVCL_RR25
DR   Wikidata; Q54971865
RX   PubMed=26055179;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Doubling time: 117.8 hours (PubMed=26055179).
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Homozygous (from parent cell line).
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1738 ! TCCSUP
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
//
RX   PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002;
RA   Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M.,
RA   Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.;
RT   "Drug-resistant urothelial cancer cell lines display diverse
RT   sensitivity profiles to potential second-line therapeutics.";
RL   Transl. Oncol. 8:210-216(2015).
//